Sort   by:  
 Page size 
UnknownBayesian adaptive randomized trial design for patients with recurrent glioblastoma.
Not available
S-EPMC3434985 | biostudies-literature
UnknownNeoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma.
Not available
S-EPMC8626557 | biostudies-literature
UnknownFirst-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.
Not available
S-EPMC12365897 | biostudies-literature
UnknownSimultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI).
Not available
S-EPMC6107417 | biostudies-literature
UnknownDoes Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Not available
S-EPMC5070573 | biostudies-literature
UnknownPatients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Not available
S-EPMC5015426 | biostudies-literature
UnknownThe MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Not available
S-EPMC4633927 | biostudies-literature
UnknownEmerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.
Not available
S-EPMC7686464 | biostudies-literature
UnknownTLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
Not available
S-EPMC11078958 | biostudies-literature
UnknownDendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients.
Not available
S-EPMC10543402 | biostudies-literature
Sort   by:  
 Page size